Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
December 11, 2025 / Mazdutide / Adolescent Obesity / Weight Loss Treatment / Clinical Trial China / Metabolic Health
Mazdutide showed significant BMI and weight reduction, plus metabolic improvements, in Chinese adolescents with obesity over 12 weeks, with no serious adverse events. A Phase 3 trial is planned, addressing a key treatment gap in pediatric obesity care.
Curating evidence-based lifestyle recommendations for obesity management
December 12, 2025 / Obesity Management / Time-Restricted Eating / GLP-1 Therapy / Nutritional Deficiency / Cardiometabolic Health
Effective obesity management requires curated, evidence-based lifestyle interventions, including personalized diet, exercise, and time-restricted eating. Special attention is needed for patients on GLP-1 therapies due to risk of nutritional deficiencies and sarcopenia, especially with higher-dose treatment.
Harvard gut discovery could change how we treat obesity and diabetes
December 14, 2025 / Gut Microbiome / Obesity Treatment / Type 2 Diabetes / Metabolic Health / Liver Metabolites
Harvard researchers identified gut-derived metabolites that influence liver metabolism and insulin sensitivity, offering potential new therapeutic targets for obesity and type 2 diabetes. Diet and genetics impact these metabolites, highlighting the gut-liver axis as key to metabolic disease management.
Fibulin-7 in progenitor cells promotes adipose tissue fibrosis and disrupts metabolic homeostasis in obesity
December 12, 2025 / Fibulin-7 / Adipose Tissue Fibrosis / Obesity Treatment / Metabolic Dysfunction / TGF-β Signaling
Fibulin-7, produced by adipogenic precursor cells, promotes adipose tissue fibrosis and disrupts metabolic balance in obesity. Targeting FBLN7—via gene knockout or neutralizing antibodies—reduces fibrosis and improves metabolic health, identifying it as a promising therapeutic target.
Zealand Pharma and OTR to develop metabolic disease therapeutics
December 12, 2025 / Zealand Pharma / Metabolic Disease / Obesity Treatment / Drug Development / OTR Therapeutics
Zealand Pharma and OTR Therapeutics have partnered to co-develop novel therapies targeting obesity and metabolic diseases, combining OTR’s discovery platform with Zealand’s clinical expertise. The collaboration may yield transformative treatments and includes potential milestones totaling $2.5 billion.
Pfizer’s $2bn+ obesity bet, and other weight-loss news
December 11, 2025 / Pfizer Obesity Pipeline / GLP-1 Therapy / Weight Loss Drug / Metabolic Disease / Pharma Partnerships
Pfizer licensed GLP-1 candidate YP05002 from Fosun Pharma, expanding its obesity pipeline to six assets after setbacks with prior compounds. Industry momentum continues, with promising data from Zealand, Structure, Ascletis, Wave Life Sciences, and Boehringer Ingelheim.
Eli Lilly Drug for 3 Obesity Targets Sets New High Bar for Weight Loss in a Clinical Trial
December 11, 2025 / Eli Lilly / Retatrutide Trial / Obesity Treatment / Weight Loss Drug / GLP-1 GIP Glucagon
Eli Lilly’s triple agonist retatrutide achieved 28.7% weight loss in a Phase 3 trial, surpassing prior benchmarks. However, high discontinuation rates—linked to side effects and rapid weight loss—highlight the need for careful dosing and patient management.
Prolynx banks $70M for longer-lasting obesity drugs
December 11, 2025 / Prolynx / Long-Acting Obesity Drugs / GLP-1 Therapy / Sustained Release / Semaglutide Innovation
Prolynx raised $70M to develop long-acting obesity drugs using proprietary sustained-release technology. Targeting monthly or quarterly dosing, their pipeline includes extended-release versions of semaglutide, dual GLP-1/GIPR agonists, and amylin therapies to improve adherence and minimize side effects.
Surprising new function of immune cells uncovered: Excess weight loss prevention
December 10, 2025 / Neutrophils / Fat Metabolism / Obesity Research / Immune System / Weight Loss Regulation
UC San Diego researchers discovered that neutrophils infiltrate fat tissue during metabolic stress to prevent excess fat loss by suppressing fat breakdown. This immune-metabolic interaction may offer new therapeutic targets for obesity, metabolic disorders, and unintended weight loss.
Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study
December 9, 2024 / Fermented Beverage / Obesity Diabetes Pathways / Bioactive Compounds / Network Pharmacology / Insulin Resistance
A sterilized fermented beverage containing bioactive flavonoids and alkaloids showed, in computational modeling, multi-target effects on insulin, lipid, and inflammatory pathways relevant to obesity and type 2 diabetes. Experimental and clinical validation is needed to confirm therapeutic potential.
Tackle liver health and obesity, or risk non-communicable disease failure
December 12, 2025 / Liver Health / Obesity Policy / Type 2 Diabetes / Metabolic Disease / EU NCD Strategy
Experts warn that excluding liver health from the EU’s NCD strategy undermines efforts to tackle obesity and metabolic disease. Liver disease, tightly linked to obesity and type 2 diabetes, requires early detection, equitable access to treatment, and integrated prevention policies.
Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
December 16, 2025 / Rona Therapeutics / INHBE siRNA / Obesity Treatment / RNAi Therapy / Phase 1 Trial
Rona Therapeutics completed initial Phase 1 dosing of RN3161, a GalNAc-conjugated siRNA targeting INHBE for obesity. Early data show favorable safety and support the potential for durable, infrequent dosing as a novel metabolic therapy.
MASH: Is Semaglutide Right for You?
December 15, 2025 / Semaglutide / MASH Treatment / Fatty Liver Disease / GLP-1 Receptor Agonist / Liver Fibrosis
Semaglutide received accelerated FDA approval for moderate to severe MASH after Phase 3 data showed significant resolution of steatohepatitis and fibrosis improvement. Benefits are greatest in patients with obesity or diabetes, while careful patient selection and monitoring remain essential.
Evaluation of Albumin Platelet Product for Fibrosis Detection in MASLD
December 11, 2025 / MASLD Screening / APP Biomarker / Liver Fibrosis Detection / Diabetes Cirrhosis Risk / Noninvasive Liver Test
A new study shows the albumin platelet product (APP) biomarker performs as well as FIB-4 and better for cirrhosis detection in MASLD patients with diabetes, supporting APP’s use with diabetes-specific thresholds for improved fibrosis screening accuracy.
FDA qualifies 1st AI drug development tool for reading MASH images
December 9, 2025 / AIM-NASH / MASH Drug Development / AI Liver Biopsy / FDA Qualified Tool / PathAI Technology
The FDA qualified AIM-NASH, PathAI’s AI-based tool, to assist drug developers in evaluating MASH liver biopsies during clinical trials. This technology standardizes scoring of inflammation, fat, and fibrosis, potentially accelerating and improving consistency in MASH drug development.
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
December 12, 2025 / Denifanstat / Acne Treatment / FASN Inhibitor / MASH Therapy / Sagimet Ascletis
China’s NMPA has accepted Ascletis’ NDA for denifanstat, a FASN inhibitor licensed from Sagimet, for moderate to severe acne. Denifanstat has also shown promise in MASH, with development underway globally for both dermatologic and metabolic-fibrotic indications.
Metabolic syndrome affects nearly four in ten US adults as rates climb in older and Black populations
December 14, 2025 / Metabolic Syndrome / Cardiovascular Risk / Health Disparities / Hypertriglyceridemia Trends / NHANES Study
Nearly 39% of U.S. adults now meet criteria for metabolic syndrome, with significant increases among older adults and non-Hispanic Black populations. Findings highlight persistent disparities and underscore the need for targeted prevention and improved cardiometabolic care access.
Weight-Adjusted Waist Index Can Predict CVD Risk in Cardiovascular Kidney Metabolic Syndrome
December 12, 2025 / WWI Index / CKM Syndrome / Cardiovascular Risk / Central Adiposity / Obesity Assessment
The weight-adjusted waist index (WWI) outperformed other obesity measures in predicting cardiovascular disease risk among individuals with early-stage cardiovascular-kidney-metabolic (CKM) syndrome. WWI may serve as a superior tool for early risk stratification and intervention planning.
Advanced Cardiovascular-Kidney-Metabolic Syndrome Increases Sarcopenia Risk
December 12, 2025 / CKM Syndrome / Sarcopenia Risk / Muscle Loss / Physical Inactivity / Cardiometabolic Health
Advancing cardiovascular-kidney-metabolic (CKM) syndrome stages significantly increase the risk of sarcopenia, with physical inactivity compounding this effect. CKM staging may serve as a useful tool for identifying high-risk individuals needing early muscle health screening and targeted interventions.
Advancements in diabetes drug development
December 10, 2025 / Diabetes Drug Development / Type 1 Diabetes / Type 2 Diabetes / GLP-1 Therapy / Metabolic Disease
Advances in diabetes drug development are shifting care beyond glucose control toward disease modification. Novel immune therapies for type 1 diabetes and multi-target agents such as GLP-1, GIP, and SGLT2 modulators for type 2 diabetes improve metabolic, cardiovascular, and renal outcomes.